Biocure Technology Inc. (CSE:CURE.X)

Market Cap	3.76M
Revenue (ttm)	n/a
Net Income (ttm)	-4.06M
Shares Out	94.00M
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	7,363
Open	0.0400
Previous Close	0.0250
Day's Range	0.0400 - 0.0400
52-Week Range	0.0100 - 0.3150
Beta	2.39
RSI	48.16
Earnings Date	Apr 29, 2025

About Biocure Technology

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-β for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: CURE.X